Table 2.
Clinical variables associated with cryptococcosis in HIV-uninfected patients.
| Variable | No. (%) (n = 47) |
|---|---|
| Receipt of immunosuppressive agents Prednisone only Prednisone + MMF + tacrolimus Prednisone + MMF Prednisone + others (tocilizumab) Inhaled corticosteroids Others (methotrexate, interferon, thalidomide, blinatumomab) | 38/46 (82%)5/46 (11%)25/46 (54%)2/46 (4%)1/46 (2%)2/46 (4%)3/46 (7%) |
| Immunocompromising condition | |
| Solid organ transplantation | 24/47 (51%) |
| Autoimmune disease | 8/47 (17%) |
| Malignancy | 7/47 (14%) |
| Cirrhosis | 4/47 (8%) |
| Asthma/COPD on inhaled steroids | 2/47 (4%) |
| Normal host | 2/47 (4%) |
| Type of transplant | |
| Liver | 2/24 (8%) |
| Heart | 1/24 (4%) |
| Kidney | 20/24 (83%) |
| Liver/Kidney | 1/24 (4%) |
| Weaning of immunosuppressive agents after diagnosis of cryptococcosis | 31/38 (82%) |
| High dose corticosteroid use for C-IRIS | 5/47 (11%) |
Data presented as no. (%) unless indicated otherwise.
C-IRIS, cryptococcus-associated immune reconstitution inflammatory syndrome; COPD, chronic obstructive pulmonary disease; MMF, mycophenolate mofetil.